SmartInsulin ADME and IND-enabling Preclinical Studies

SmartInsulin ADME 和支持 IND 的临床前研究

• 批准号: 7901274
• 负责人: TODD C ZION
• 金额: $ 157.83万
• 依托单位: SMARTCELLS, INC.
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-25 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7901274
• 关键词: ADME Study; Address; Affinity; Amylases; Animals; Antibodies; Autopsy; Binding; Biological Assay; Blood Glucose; Canis familiaris; Cavia; Cells; Clinical Research; Complement; Complete Blood Count; Complications of Diabetes Mellitus; Contracts; Control Groups; Diabetes Mellitus; Diagnostic; Diet; Dose; Drug Formulations; Drug Kinetics; Exhibits; Family suidae; Felis catus; Gel; Glucose; Glycosylated Hemoglobin; Glycosylated hemoglobin A; Goals; Grant; Half-Life; Heart Diseases; Hepatocyte; Histopathology; Hour; Human; Hypoglycemia; In Vitro; Incidence; Inflammatory Response; Injection of therapeutic agent; Insulin; Insulin-Dependent Diabetes Mellitus; Kidney Diseases; Label; Measures; Medical; Mole the mammal; Neuropathy; Organ; Oryctolagus cuniculus; Patients; Peripheral Blood Mononuclear Cell; Pharmacology; Pharmacology and Toxicology; Phase; Plasma; Polymers; Preparation; Prevalence; Procedures; Protamine Zinc Insulin; Pump; Qualifying; Radiolabeled; Rattus; Recombinants; Retinal Diseases; Risk; Safety; Scintillation Counting; Serum; Site; Small Business Innovation Research Grant; Solutions; Sprague-Dawley Rats; Stroke; System; Thymidine; Time; Tissues; Toxic effect; Toxicokinetics; Toxicology; United States; Vendor; assay development; base; clinically relevant; cost; crosslink; design; diabetes control; diabetic; diabetic rat; dosage; glucose monitor; glycemic control; glycosylated insulin; in vivo; interest; minimally invasive; nanostructured; non-diabetic; novel; pre-clinical; preclinical study; prospective; radiotracer; receptor binding; uptake

DESCRIPTION (provided by applicant): SmartCells is developing SmartInsulin?,which is intended to be a once-a-day, self- regulating insulin injection for the treatment of Type I diabetes. It is designed as a "drop- in" replacement product for the 4 million insulin-using diabetics in the United States. SmartInsulin is designed to provide significant benefits to insulin-dependent diabetics including fewer injections, less frequent blood sugar monitoring, reduced incidence of low blood sugar levels and single-dose control of both fasting and mealtime blood sugar levels. SmartInsulin is a nanostructured material that self-assembles from two biomolecular building blocks: a glycosylated insulin-polymer conjugate (IPC) and a multivalent glucose-binding molecule (GBM). The work covered in this submission is built on the successful results of a two-year NIH SBIR Phase 1 grant, an NIH SBIR Phase 2 grant, and preliminary results from a DOD grant regarding the safety and efficacy of SmartInsulin in large animal models. These results show that SmartInsulin has met its "proof-of-concept" technical goals, but IND- enabling studies must be conducted in order to bring SmartInsulin to the clinic. This requires very detailed and expensive GLP toxicity/ADME studies and a GMP manufacturing process. This project is intended to provide a clear path to IND-enabling GLP preclinical studies for SmartInsulin. In this grant application, SmartCells aims to qualify and validate the necessary pharmacology assays, conduct GLP-pharmacology, toxicity, and pharmacokinetic/ADME studies, leading to an IND submission with the FDA. The impacts to public health as a result of this project are potentially significant. Poor glycemic control has been shown to cause a host of diabetic complications which result in over $54 billion annually in medical costs. The landmark Diabetes Control and Complications Trial (DCCT) and the UK Prospective Diabetes Study (UKPDS) have clinically proven that tighter glycemic control, as measured by lower glycosylated hemoglobin A1c (HbA1c) levels, significantly reduces the incidence of these complications. SmartInsulin is designed to provide tighter glycemic control, lowered HbA1c levels, and thus decreased incidence of diabetic complications.

描述（由申请方提供）：SmartCells正在开发SmartInsulin？，其旨在成为一天一次的自我调节胰岛素注射剂，用于治疗I型糖尿病。它被设计成一种“插入式”替代产品，用于美国400万使用胰岛素的糖尿病患者。SmartInsulin旨在为胰岛素依赖型糖尿病患者提供显着的益处，包括更少的注射，更少的血糖监测频率，降低低血糖水平的发生率以及空腹和餐时血糖水平的单次剂量控制。SmartInsulin是一种纳米结构材料，由两种生物分子构建块自组装而成：糖基化胰岛素-聚合物缀合物（IPC）和多价葡萄糖结合分子（GBM）。本次提交的工作是建立在为期两年的NIH SBIR第1阶段资助，NIH SBIR第2阶段资助的成功结果以及国防部关于SmartInsulin在大型动物模型中的安全性和有效性的初步结果的基础上。这些结果表明，SmartInsulin已经达到了其“概念验证”的技术目标，但必须进行IND使能研究，以便将SmartInsulin推向临床。这需要非常详细和昂贵的GLP毒性/ADME研究和GMP生产工艺。该项目旨在为SmartInsulin的IND支持GLP临床前研究提供明确的途径。在这项拨款申请中，SmartCells旨在鉴定和验证必要的药理学试验，进行GLP药理学，毒性和药代动力学/ADME研究，从而向FDA提交IND申请。该项目对公众健康的影响可能很大。血糖控制不良已被证明会导致许多糖尿病并发症，每年导致超过540亿美元的医疗费用。具有里程碑意义的糖尿病控制和并发症试验（DCCT）和英国前瞻性糖尿病研究（UKPDS）已在临床上证明，更严格的血糖控制（通过较低的糖化血红蛋白A1 c（HbA 1c）水平测量）可显著降低这些并发症的发生率。SmartInsulin旨在提供更严格的血糖控制，降低HbA 1c水平，从而降低糖尿病并发症的发生率。